



Pascal Frei

Kontakt

Pascal Frei

Publikationen (8)

Vavricka S, Biedermann L, Michetti P, Straumann A, Misselwitz B, Scharl M, Manser C, Greuter T, Zeitz J, Frei P, Borovicka J, Seibold F, Schoepfer A, Rogler G, Spasojevic M. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. *Dig Dis* 2017; 35:423-432.

Zeitz J, Rogler G, Fried M, Sulz M, Vavricka S, Scharl S, Misselwitz B, Frei P, Biedermann L, Labenz C, Fournier N, Scharl M. Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. *Inflamm Intest Dis* 2017; 1:172-181.

Bontà J, Rogler G, Fried M, Scharl S, Vavricka S, Sulz M, Biedermann L, Frei P, Zeitz J, Scharl M. Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience. *Eur J Gastroenterol Hepatol* 2016; 28:1329-34.

Spalinger M, Scharl M, Rogler G, Fried M, Vavricka S, Scharl S, Frei P, Sulz M, Rossel J, Biedermann L, Zeitz J. Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. *PloS one* 2016; 11:e0160215.

Madanchi M, Rogler G, Vavricka S, Frei P, Biedermann L, Sulz M, Scharl S, Samaras P, Barthel C, Zeitz J, Scharl M. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience. *Digestion* 2016; 94:1-8.

Vögelin M, Rogler G, Fried M, Sulz M, Zeitz J, Scharl S, Vavricka S, Frei P, Biedermann L, Scharl M. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. *PloS one* 2016; 11:e0155218.

Spalinger M, Scharl M, Rogler G, Fried M, Vavricka S, Scharl S, Frei P, Sulz M, Rossel J, Zeitz J, Biedermann L, Voegelin M. The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. *Digestion* 2016; 93:182-92.

Barthel C, Rogler G, Wiegand N, Sulz M, Fried M, Vavricka S, Frei P, Scharl M, Scharl S, Wiegand S, Biedermann L. Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey. *Nutr J* 2015; 14:78.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch